

NCT ID	NCT06253520
Title	Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Phase	Phase 1
Date Added	2024-02-12
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06043713
Title	Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
Phase	Phase 1
Date Added	2023-09-21
Location	Washington, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Suspended
Drugs	Bendamustine, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03638206
Title	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Phase	Phase 1/Phase 2
Date Added	2018-08-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CAR-T cell immunotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05141474
Title	Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Phase	Early Phase 1
Date Added	2021-12-02
Location	Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03832855
Title	Assessing the Immunogenicity of pING-hHER3FL
Phase	Phase 1

Date Added	2019-02-06
Location	North Carolina, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	pING-hHER3FL
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03829462
Title	Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Phase	Phase 3
Date Added	2019-02-04
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Irinotecan, Regorafenib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05464030
Title	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Phase	Phase 1
Date Added	2022-07-19
Location	California, United States Rhode Island, United States Texas, United States Canada Japan South Korea Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	M9140
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04432857
Title	AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Phase	Phase 1
Date Added	2020-06-16
Location	Missouri, United States Texas, United States Utah, United States Virginia, United States France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	AN0025, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT04660812

Title	An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Phase	Phase 1, Phase 2
Date Added	2020-12-09
Location	Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy South Korea Spain United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Completed
Drugs	AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab
Tags	MSS/ MMRp
NCT ID	NCT03994601
Title	An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Phase	Phase 1
Date Added	2019-06-21
Location	California, United States Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canada Chile France Italy Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	BMS-986288, Nivolumab, Opdivo
Tags	MSI-H/ MMRd, MSS/ MMRp